Noah Stansfield

A2B694 is being evaluated for the treatment of patients with mesothelin-expressing solid tumors that have lost HLA-A*02 expression.

Lawrence R. Lustig, MD, discussed promising early results from the phase 1/2 CHORD trial evaluating Decibel Therapeutics and Regenerons’ DB-OTO.

Verismo intends to go forward with plans for the phase 1 CELESTIAL-301 clinical trial, which the company expects to initiate in the second half of this year.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

VERVE-102 is intended to reduce LDL-C in patients with heterozygous familial hypercholesterolemia or premature coronary artery disease.

The cofounder, chairman, and CEO of Kriya Therapeutics discussed the company’s goal of bringing gene therapy to a much broader population of patients.

Updated data including a sixth patient and longer follow-up was presented at ASGCT’s 2024 Meeting.

In observance of World Lupus Day, held annually on May 10, we took a look back at a year of progress in bringing CAR-T to this autoimmune disease.

In terms of safety, NGGT001 was deemed well-tolerated.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

The first patient in the trial, which is evaluating NTLA-2001 for the treatment of ATTR Amyloidosis, was enrolled at MedStar Washington Hospital Center.

The company anticipates that initial data from the study will be announced next year.

Terence R. Flotte, MD, the vice president of ASGCT, discussed what attendees can expect at the ASGCT Annual Meeting this year.

Testing for the presence of neutralizing antibodies is an essential step before patients can receive Beqvez.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Paula Cannon, PhD, the president elect of ASGCT, discussed things to look forward to at the upcoming Meeting that will be held from May 7 to 11, in Baltimore, MD.

NKGen anticipates that it will dose the first patient in the study in the second half of this year.

Jessica S. Little, MD, a transplant infectious diseases physician at Dana-Farber Cancer Institute, discussed research on fungal infections in patients receiving HSCT and CAR-T.

In anticipation of Bladder Cancer Awareness Month, CGTLive® has decided to take a closer look at this noninterventional real-world study.

The first-in-human, open-label, single-arm trial is expected to enroll 9 participants over the course of a year.

Emilie Aschenbrenner, PharmD, BCOP, a hematology coordinator for pharmacy at Froedtert and the Medical College of Wisconsin, discussed the advantages of each of the 2 modalities in the third and second line settings.

AlloNK is being administered in the trial alone or alongside 1 of 2 antiCD20 monoclonal antibodies: rituximab or obinutuzumab.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

The EC’s decision comes several weeks after the FDA approved cilta-cel for a similar expanded indication.

The FDA is requesting more CMC information, specifically with regard to validation requirements for specific manufacturing and release testing methods.

The results come from the randomized, double-masked, placebo-controlled phase 3 REFLECT clinical trial (NCT03293524).

At the 90 day timepoint, the patient showed improvements in swallowing compared to their own natural history data, as measured by videofluoroscopic swallowing studies.

Alexis Kuhn, PharmD, BCOP, a pediatric oncology pharmacist at Mayo Clinic, discussed the incorporation of the recently FDA-approved gene therapies for SCD and TDT into the work of pharmacists.

The FDA has requested that black box warnings related to secondary cancer risks be added to all 6 CAR-T therapies currently on the market.

The 3 new clinical trials will take place in the United States and are intended to increase the amount of accumulated data supporting the use of Adstiladrin in NMIBC.